Stockscreener 앱 받기
11.66
1.18%
-0.156
Beta Bionics Inc 주식(BBNX)의 최신 뉴스
BofA Securities Maintains Beta Bionics(BBNX.US) With Hold Rating, Raises Target Price to $13 - Moomoo
Piper Sandler Maintains Beta Bionics(BBNX.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Beta Bionics | 8-K: Current report - Moomoo
Beta Bionics (NASDAQ: BBNX) investors approve directors and auditor - Stock Titan
Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development - Sahm
Beta Bionics Expects Commercialization of Mint Insulin Patch Pump in 2027 - Moomoo
[144] Beta Bionics, Inc. SEC Filing - Stock Titan
Beta Bionics says Mint commercialization expected by end-Q2 2027, subject to FDA clearance - TradingView
Mint patch pump launch target set for Q2 2027 by Beta Bionics (NASDAQ: BBNX) - Stock Titan
No-recharge insulin patch pump targets 2027 launch pending FDA clearance - Stock Titan
BBNX Maintains by B of A Securities -- Price Target Lowered to $11.00 - GuruFocus
Beta Bionics Price Target Cut to $11.00/Share From $23.00 by B of A Securities - Moomoo
Beta Bionics, Inc. Stock 12‑Month Price Target Cut to $19.18, Implies 103% Upside - TradingView
BofA Adjusts Price Target on Beta Bionics to $11 From $23 - Moomoo
BofA Securities Maintains Beta Bionics(BBNX.US) With Hold Rating, Cuts Target Price to $11 - Moomoo
BBNX Forecast — Price Target — Prediction for 2027 - TradingView
Beta Bionics | SCHEDULE 13G/A: Others - Moomoo
Eventide (BBNX) reports 5.95M shares — 13.4% stake in Beta Bionics - Stock Titan
RTW Investments reports 2.0M-share stake in Beta Bionics (NASDAQ: BBNX) - Stock Titan
Beta Bionics Touts Pharmacy Push, iLet Momentum and 2027 Mint Patch Pump Plans - Yahoo Finance
BBNX: Mint patch pump launch set for end of 2027, with pharmacy channel driving growth - TradingView
Farallon and Zone Holdings disclose ownership in Beta Bionics (BBNX) — 13G/A - Stock Titan
Here's Why We're Not Too Worried About Beta Bionics' (NASDAQ:BBNX) Cash Burn Situation - Yahoo Finance
Number of shareholders of Beta Bionics, Inc. – NASDAQ:BBNX - TradingView
Soleus group files 9.8% stake in Beta Bionics (NASDAQ: BBNX) - Stock Titan
Beta Bionics, Inc. (BBNX) Stock Analysis: Exploring a Potential 93% Upside in Medical Devices - DirectorsTalk Interviews
A Quick Look at Today's Ratings for Beta Bionics(BBNX.US), With a Forecast Between $16 to $20 - Moomoo
Beta Bionics, Inc. (BBNX) soars 10.3%: Is further upside left in the stock? - MSN
Beta Bionics (BBNX) price target decreased by 11.15% to 20.99 - MSN
Midday Stock Roundup: Tech stocks rally - Orange County Business Journal
Beta Bionics, Inc. (BBNX) reports Q1 loss, misses revenue estimates - MSN
Beta Bionics to Present at the Bank of America Securities Health Care Conference - The Manila Times
Beta Bionics projects $131M-$136M 2026 revenue and raises gross margin outlook to 57.5%-59.5% - MSN
BBNX.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Beta Bionics, Inc. (NASDAQ:BBNX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Allogene Therapeutics (ALLO) - The Globe and Mail
BBNX (Beta Bionics Inc.) posts narrower Q4 2025 loss than consensus estimates, sending shares up more than six percent.Analyst Recommended Stocks - Xã Thanh Hà
Lake Street reiterates Buy on Beta Bionics stock on Q1 beat By Investing.com - Investing.com Australia
0.32%
0.17%
자본화:
|
볼륨(24시간):